Chiara Riganti
Overview
Explore the profile of Chiara Riganti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
263
Citations
5632
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lacconi V, Massimiani M, Antonello G, Gasco P, Bernardini R, Ferrari C, et al.
Front Toxicol
. 2025 Jan;
6():1508598.
PMID: 39839550
Solid lipid nanoparticles (SLNs) have gained interest as drug delivery carriers due to their efficient cellular internalization and increased therapeutic effect of the loaded drug, with minimal side effects. Although...
2.
Erin N, Tavsan E, Haksever S, Yerlikaya A, Riganti C
Breast Cancer Res Treat
. 2025 Jan;
PMID: 39792296
Purpose: Mammary carcinoma is comprised heterogeneous groups of cells with different metastatic potential. 4T1 mammary carcinoma cells metastasized to heart (4THM), liver (4TLM) and brain (4TBM) and demonstrate cancer-stem cell...
3.
Branco H, Xavier C, Riganti C, Vasconcelos M
Biochim Biophys Acta Rev Cancer
. 2024 Dec;
1880(1):189244.
PMID: 39672279
In the past years, increasing attention has been paid to the role of extracellular vesicles (EVs) as mediators of intercellular communication in cancer. These small size particles mediate the intercellular...
4.
Castruccio Castracani C, Breda L, Papp T, Guerra A, Radaelli E, Assenmacher C, et al.
Blood
. 2024 Dec;
145(1):98-113.
PMID: 39656107
X-linked sideroblastic anemia (XLSA) is a congenital anemia caused by mutations in ALAS2, a gene responsible for heme synthesis. Treatments are limited to pyridoxine supplements and blood transfusions, offering no...
5.
Sapino S, Peira E, Chirio D, Chindamo G, Accomasso G, Vercelli C, et al.
Int J Pharm
. 2024 Nov;
668:124970.
PMID: 39566701
Osteosarcoma (OSA) is a bone cancer that affects both humans and animals, with dogs being particularly vulnerable. Standard therapy is often limited by multidrug resistance (MDR), primarily due to the...
6.
Barbanente A, Kopecka J, Vitone D, Niso M, Rizzi R, Cuocci C, et al.
J Med Chem
. 2024 Nov;
67(22):20118-20134.
PMID: 39552021
Pancreatic cancer, with its increasing incidence and lowest 5-year survival rate, is predicted to become the second leading cause of cancer deaths by 2030. Current clinical trials have shown limited...
7.
Digiovanni S, Lorenzati M, Bianciotto O, Godel M, Fontana S, Akman M, et al.
Fluids Barriers CNS
. 2024 Nov;
21(1):89.
PMID: 39487455
Background: Glioblastoma multiforme (GBM) is an aggressive tumor, difficult to treat pharmacologically because of the blood-brain barrier (BBB), which is rich in ATP-binding cassette (ABC) transporters and tight junction (TJ)...
8.
Sorge M, Savore G, Gallo A, Acquarone D, Sbroggio M, Velasco S, et al.
EMBO Mol Med
. 2024 Sep;
16(10):2450-2484.
PMID: 39271959
Defining the molecular mechanisms underlying cardiac resilience is crucial to find effective approaches to protect the heart. A physiologic level of ROS is produced in the heart by fatty acid...
9.
La Vecchia S, Fontana S, Salaroglio I, Anobile D, Digiovanni S, Akman M, et al.
Cancer Lett
. 2024 Sep;
604:217221.
PMID: 39245263
Immune checkpoints inhibitors (ICIs) as anti-PD-1/anti-PD-L1 have been approved as first-line treatment in patients with non-small cell lung cancer (NSCLC), but only 25 % of patients achieve durable response. We...
10.
Akman M, Monteleone C, Doronzo G, Godel M, Napoli F, Merlini A, et al.
J Exp Clin Cancer Res
. 2024 Aug;
43(1):244.
PMID: 39198838
No abstract available.